TH9507 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-10. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
=== World War I === In July 1914—shortly before the outbreak of World War I—Hahn was recalled to active duty with the army in a Landwehr regiment. They marched through Belgium, where the platoon he commanded was armed with captured machine guns. He was awarded the Iron Cross (2nd Class) for his part in the First Battle of Ypres. He was a joyful participant in the Christmas truce of 1914, and was commissioned as a lieutenant. In mid-January 1915, he was summoned to meet chemist Fritz Haber, who explained his plan to break the trench deadlock with chlorine gas. Hahn raised the issue that the Hague Convention banned the use of projectiles containing poison gases, but Haber explained that the French had already initiated chemical warfare with tear gas grenades, and he planned to get around the letter of the convention by releasing gas from cylinders instead of shells.
=== Canada === Beak trimming is legal but regulated in Canada. The National Farm Animal Care Council's 2016 Poultry Code of Practice urges to 'make every effort to manage breeders so that physical alterations, such as beak trimming, are not necessary'; should it prove necessary, however, infrared treatment is recommended over hot blade treatment.
Animals and plants have evolved to synthesise a vast array of poisonous products including secondary metabolites, peptides and proteins that can act as inhibitors. Natural toxins are usually small organic molecules and are so diverse that there are probably natural inhibitors for most metabolic processes. The metabolic processes targeted by natural poisons encompass more than enzymes in metabolic pathways and can also include the inhibition of receptor, channel and structural protein functions in a cell. For example, paclitaxel (taxol), an organic molecule found in the Pacific yew tree, binds tightly to tubulin dimers and inhibits their assembly into microtubules in the cytoskeleton. Many natural poisons act as neurotoxins that can cause paralysis leading to death and function for defence against predators or in hunting and capturing prey. Some of these natural inhibitors, despite their toxic attributes, are valuable for therapeutic uses at lower doses. An example of a neurotoxin are the glycoalkaloids, from the plant species in the family Solanaceae (includes potato, tomato and eggplant), that are acetylcholinesterase inhibitors. Inhibition of this enzyme causes an uncontrolled increase in the acetylcholine neurotransmitter, muscular paralysis and then death. Neurotoxicity can also result from the inhibition of receptors; for example, atropine from deadly nightshade (Atropa belladonna) that functions as a competitive antagonist of the muscarinic acetylcholine receptors.
Sources: en.wikipedia.org
=== 1. Gingiva === The gingiva is the visible soft-tissue component of the periodontium and forms a biological seal around the cervical region of the teeth, protecting the underlying periodontal structures from mechanical trauma and microbial invasion.
Where space is limited, such as on pressure gauges, name plates, graph labels, and table headings, the use of a modifier in parentheses, such as "kPa (gauge)" or "kPa (absolute)", is permitted. In non-SI technical work, a gauge pressure of 32 psi (220 kPa) is sometimes written as "32 psig", and an absolute pressure as "32 psia", though the other methods explained above that avoid attaching characters to the unit of pressure are preferred. Gauge pressure is the relevant measure of pressure wherever one is interested in the stress on storage vessels and the plumbing components of fluidics systems. However, whenever equation-of-state properties, such as densities or changes in densities, must be calculated, pressures must be expressed in terms of their absolute values. For instance, if the atmospheric pressure is 100 kPa (15 psi), a gas (such as helium) at 200 kPa (29 psi) (gauge) (300 kPa or 44 psi [absolute]) is 50% denser than the same gas at 100 kPa (15 psi) (gauge) (200 kPa or 29 psi [absolute]). Focusing on gauge values, one might erroneously conclude the first sample had twice the density of the second one.
(1881), classical scholar and educator Richard James Horatio Gottheil (1881), Zionist scholar, founder of the first Jewish fraternity Zeta Beta Tau Harry Thurston Peck (1881), literary critic and editor of The Bookman A. V. Williams Jackson (1883), specialist on Indo-European languages Charles Knapp (1887), classical scholar Frank Moore Colby (1888), historian and editor of The New International Encyclopedia Charles Sears Baldwin (1888), scholar and professor of rhetoric at Yale University John Dyneley Prince (1888), linguist; U.S. ambassador to Yugoslavia George Louis Beer (1892), renowned historian of the "Imperial school" Benjamin Lord Buckley (1892), educator, founder and headmaster of Buckley School Judah A. Joffe (1893), Yiddish philologist William Robert Shepherd (1893), cartographer, historian John Driscoll Fitz-Gerald (1895), Hispanic scholar Joel Elias Spingarn (1895), professor of comparative literature Mortimer Lamson Earle (1896), classical scholar Alfred L. Kroeber (1896), pioneering cultural anthropologist William Popper (1896), Orientalist and professor Frederick Paul Keppel (1898), educator, former president of the Carnegie Corporation of New York Frank Sutliff Hackett (1899), educator, founder of Riverdale Country School John Erskine (1900), Great Books pioneer Alexander Goldenweiser (1902), Russian-born anthropologist and sociologist Emanuel Goldenweiser (1903), economist and president of the American Economic Association Robert Livingston Schuyler (1903), scholar on American history, president of the American Historical Association Carlton J. H.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.